This study aims to explore the clinical efficacy of CpG-based therapy for treating hepatocellular carcinoma (HCC) by skewing polarization toward M1 macrophage from M2.
Methods:
Pulmonary metastasis rate, overall survival time, and remission rate of 10 patients with HCC treated with transcatheter arterial chemoembolization (TACE) combined with CpG therapy and 10 age-, gender-, and TNM0-matched patients treated with TACE (control group) were compared.
Results:
No pulmonary metastasis rate was 70% in the combined treatment group and 40% in the control group, respectively; and the differences between the two groups were statistically significant (p < 0.05). Median overall survival time was 22 months in the combined treatment group, compared with 6.65 months in the control group (p < 0.05). Remission rate in the combined treatment group (70%) was higher than in the control group (30%), but the differences between these two groups were not statistically significant (p > 0.05).
Conclusion:
Compared with TACE, CpG combined with TACE can decrease the pulmonary metastasis rate. This combined therapy can also improve the overall survival time of patients.
Get full access to this article
View all access options for this article.
References
1.
MantovaniA, AllavenaP, SicaA, et al.Cancer-related inflammation. Nature, 2008; 454:436–444.
2.
PortaC, LarghiP, RimoldiM, et al.Cellular and molecular pathways linking inflammation and cancer. Immunobiology, 2009; 214:761–777.
3.
SolinasG, MarchesiF, GarlandaC, et al.Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev, 2010; 29:243–248.
4.
JenkinsSJ, RuckerlD, CookPC, et al.Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science, 2011; 332:1284–1288.
5.
ZhouD, HuangC, LinZ, et al.Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal, 2014; 26:192–197.
6.
MosserDM, EdwardsJP. Exploring the full spectrum of macrophage activation. Nature Rev Immunol, 2008; 8:958–969.
7.
AllavenaP, SicaA, SolinasG, et al.The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit Rev Oncol Hematol, 2008; 66:1–9.
8.
VerreckFA, de BoerT, LangenbergDM, et al.Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A, 2004; 101:4560–4565.
9.
PuolakkainenP, KoskiA, VainionpääS, et al.Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Med Oncol, 2014; 31:884.
10.
Shuman MossLA, Jensen-TaubmanS, Stetler-StevensonWG. Matrix metalloproteinases: Changing roles in tumor progression and metastasis. Am J Pathol, 2012; 181:1895–1899.
11.
MantovaniA, SicaA. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol, 2010; 22:231–237.
12.
FrançoisM, Romieu-MourezR, LiM, et al.Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther, 2012; 20:187–195.
13.
SicaA, SchioppaT, MantovaniA, et al.Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer, 2006; 42:717–727.
14.
MantovaniA, SozzaniS, LocatiM, et al.Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol, 2002; 23:549–555.
15.
NoyR, PollardJW. Tumor-associated macrophages: From mechanisms to therapy, Immunity, 2014; 41:49–61.
16.
OhriCM, ShikotraA, GreenRH, et al.Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur J Respir Dis, 2009; 33:118–126.
17.
MendezS, TabbaraK, BelkaidY, et al.Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect Immun, 2003; 71:5121–5129.
18.
PashenkovM, GoëssG, WagnerC. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol, 2006; 24:5716.
19.
GuptaK, AgrawalDK. CpG oligodeoxynucleotides as TLR9 agonists: Therapeutic application in allergy and asthma. BioDrugs, 2010; 24:225–235.
20.
FleetwoodAJ, LawrenceT, HamiltonJA, et al.Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: Implications for CSF blockade in inflammation. J Immunol, 2007; 178:5245–5252.
21.
JedinakA, DudhgaonkarS, SlivaD. Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology, 2010; 215:242–249.
RyuM, KulkarniOP, RadomskaE, et al.Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss. Kidney Int, 2011; 79:189–198.
24.
GuiducciC, VicariAP, SangalettiS, et al.Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res, 2005; 65:3437–3446.
25.
YuanR, LiS, GengH, et al.Reversing the polarization of tumor-associated macrophages inhibits tumor metastasis. Int Immunopharmacol, 2017; 49:30–37.
26.
MantovaniA, SchioppaT, PortaC, et al.Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev, 2006; 25:315–322.
SicaA, AllavenaP, MantovaniA. Cancer related inflammation: The macrophage connection. Cancer Lett, 2008; 267:204–215.
29.
SicaA, SchioppaT, MantovaniA, et al.Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer, 2006; 42:717–727.
30.
SiveenKS, KuttanG. Role of macrophages in tumour progression. Immunol Lett, 2009; 123:97–102.
31.
SolinasG, GermanoG, MantovaniA, et al.Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol, 2009; 86:1065–1073.
32.
JensenTO, SchmidtH, MøllerHJ, et al.Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol, 2009; 27:3330–3337.
33.
MäkitieT, SummanenP, TarkkanenA, et al.Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci, 2001; 42:1414–1421.
34.
YuanX, LiX, ZhangQ, et al.Necrotic cells induce nonadherent peritoneal exudate cells to proliferate and differentiate into macrophage-like cells. Immunol Invest, 2013; 42:623–638.
35.
StaceyKJ, SesterDP, SweetMJ, et al.Macrophage activation by immunostimulatory DNA. Curr Top Microbiol Immunol, 2000; 247:41–58.
36.
SteidlC, LeeT, ShahSP, et al.Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med, 2010; 362:875–885.
37.
PollardJW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol, 2008; 84:623–630.
